Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages 550-552

  Yamagishi, Sho Ichi ^a   Ishibashi, Yuji ^a   Ojima, Ayako ^a   Sugiura, Tatsushi ^b   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Seiwa Clinic   (Japan)

Author keywords

Atherosclerosis; DPP 4 inhibitor; Inflammation; Linagliptin; Oxidative stress; Type 2 diabetes; Uric acid; Vascular complications; Vascular damage; Xanthine oxidase

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; URIC ACID; XANTHINE OXIDASE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG INHIBITION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; HYPERURICEMIA; IN VITRO STUDY; LETTER; MALE; MIDDLE CEREBRAL ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROSPECTIVE STUDY; RAT; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PURINES; QUINAZOLINES; URIC ACID; XANTHINE OXIDASE;

EID: 84922404737     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.023     Document Type: Article

References (11)

1. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
2. Yamagishi S, Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des 2011; 17: 4379-85.
3. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulinlike growth factor II receptor. Cardiovasc Diabetol 2013; 12: 125.
4. Nakashima S, Matsui T, Takeuchi M, Yamagishi S. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 2014, doi: 10.1055/s-0034-1371892.
5. Morishita R, Yamagishi S. A diabetes treatment strategy to reduce the risk of cardiovascular events; clinical benefits and potential of linagliptin. Immun Endoc Metab Agents Med Chem 2013; 13: 81-8.
6. Tahara N, Yamagishi S, Takeuchi M, et al. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care 2012; 35: 2618-5.
7. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-82.
8. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 2013; 167: 87-93.
9. Darsalia V, Ortsäter H, Olverling A, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: A comparison with glimepiride. Diabetes 2013; 62: 1289-96.
10. Braunersreuther V, Jaquet V. Reactive oxygen species in myocardial reperfusion injury: From physiopathology to therapeutic approaches. Curr Pharm Biotechnol 2012; 13: 97-114.
11. Rodrigo R, Fernández-Gajardo R, Gutiérrez R, et al. Oxidative stress and pathophysiology of ischemic stroke: Novel therapeutic opportunities. CNS Neurol Disord Drug Targets 2013; 12: 698-714.